Effects of Common Polymorphism rs11614913 in Hsa-miR-196a2 on Lung Cancer Risk

Zhengrong Yuan1, Xu Zeng1, Dan Yang1, Weiliu Wang1,3, Zhihua Liu1,2*

1 Department of Computational Biology and Bioinformatics, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 2 Nanjing Forestry University, Nanjing, China, 3 Department of Biotechnology, Beijing City University, Beijing, China

Abstract

Background: Emerging evidence suggests that single nucleotide polymorphisms (SNPs) in microRNA-coding genes may participate in the pathogenesis of lung cancer by altering the expression of tumor-related microRNAs. Several studies were investigated in recent years to evaluate the association between hsa-miR-196a2 rs11614913 polymorphism and increased/decreased lung cancer risk. In the present study, we performed a meta-analysis to systematically summarize the possible association.

Methodology/Principal Findings: We performed a meta-analysis of 4 case-control studies that included 2219 lung-cancer cases and 2232 cancer-free controls. We evaluated the strength of the association using odds ratios (ORs) with 95% confidence intervals (CIs). In the overall analysis, it was found that the rs11614913 polymorphism significantly elevated the risk of lung cancer (CC versus (vs.) TT OR = 1.26, 95% CI 1.07–1.49, P = 0.007; CC/CT vs. TT: OR = 1.13, 95% CI 0.98–1.29, P = 0.007; C vs. T: OR = 1.12, 95% CI 1.03–1.22, P = 0.008). In the subgroup analysis by ethnicity, statistically significantly increased cancer risk was found among Asians (CC vs. TT: OR = 1.30, 95% CI 1.10–1.54, P = 0.003; CT vs. TT: OR = 1.16, 95% CI 1.01–1.34, P = 0.039; CC vs. CT/TT: OR = 1.21, 95% CI 1.04–1.41, P = 0.012; C vs. T: OR = 1.14, 95% CI 1.05–1.25, P = 0.002). For Europeans, a significant association with lung cancer risk was found in recessive model (CC vs. CT/TT: OR = 0.63, 95% CI 0.40–0.98, P = 0.040). No publication bias was found in this study.

Conclusions/Significance: Our meta-analysis suggests that the rs11614913 polymorphism is significant associated with the increased risk of lung cancer, especially in Asians. Besides, the C allele of rs11614913 polymorphism may contribute to increased lung cancer risk.

Introduction

Lung cancer is the leading cause of cancer related deaths worldwide and the incidence rate has significantly increased in the last decades. More than one million deaths are reported worldwide every year, and the five-year survival rate is less than 15% [1,2]. Although environmental factors and lifestyle could contribute to the increased lung cancer risk, genetic factors may play a critical role in the pathogenesis of lung cancer. Furthermore, the current priority for lung cancer research is to identify genetic alterations that are directly involved in lung carcinogenesis. Molecular epidemiologic studies suggest that a great number of genetic variants have been identified to be potentially associated with lung cancer risk [3,4,5,6,7,8,9,10,11,12,13]. However, the reliable markers are still lacking and the molecular mechanisms that contribute to the pathogenesis of lung cancer remain poorly understood.

MicroRNAs (miRNAs) are small non-coding, single-stranded RNA molecules of ~ 22 nucleotides that form base-pairs with target messenger RNA (mRNAs), leading to negatively regulate their translational stability and efficiency [14,15]. Studies revealed that miRNAs regulate in various biological processes including organ development, cell growth regulation, cell differentiation, apoptosis and tumorigenesis [10,14,16,17,18]. Moreover, a growing body of evidence has supported that miRNAs play an important role in the various human cancers development and progression, including lung cancer, by regulating the expression of tumor suppressor genes or proto-oncogenes [7,9,10,19].

Single nucleotide polymorphisms (SNPs) or mutations occurring in the miRNA gene region may have effects on the function of miRNAs through altering miRNAs expression and/or maturation, consequently contributing to cancer susceptibility [15,20,21,22,23]. Recently, several studies investigated genetic
variant in the precursor or mature miRNA sequence of hsa-miR-196a2 (rs11614913 [Homo sapiens], cytosine to thymine, C—T), http://www.ncbi.nlm.nih.gov/projects/SNP as possible biomarker, which was associated with multiple kind of cancers, such as lung cancer [8,9,10,11,12,13], breast cancer [24,25,26], gastric cancer [27,28], liver cancer [29,30,31], gallbladder cancer [32], prostate cancer [33], esophageal cancer [34,35] and others [36,37]. However, the observed associations of these studies remain conflicting rather than conclusive and a single study may be too underpowered to detect slight effects of the genetic variants on cancer, especially when the sample size is relatively small. The meta-analysis could provide more credible evidence through systematically summarizing existed data. Although several meta-analyses have performed associations between the rs11614913 polymorphism and susceptibility to integrated various cancers [15,21,22,38,39,40,41,42,43,44,45], but not independent shown in lung cancer. Moreover, these meta-analyses did not enroll all of eligible case-control studies on lung cancer, thus may limit the efficacy of detecting potential associations between the rs11614913 polymorphism and lung cancer risk [15,43,44,45]. Hence, in the present study, considering the important biological function of hsa-miR-196a2 rs11614913 polymorphism in the carcinogenic process, we conducted an update meta-analysis to combine all eligible published case-control studies available and derive more precise and comprehensive estimation of the associations between rs11614913 polymorphism and the susceptibility to lung cancer.

Materials and Methods

Identification of Eligible Studies

We carried out a systematic search using PubMed, Excerpta Medica Database (EMBASE), ISI Web of Science, Cochrane Central Register of Controlled Trials, ScienceDirect, Wiley Online Library, Chinese Biomedical Literature Database (CBM) and Chinese National Knowledge Infrastructure (CNKI) databases with the last search updated on August 31, 2012. The following search terms were analyzed: “microRNA OR mir OR miRNA”, “lung cancer OR tumour OR tumor OR neoplasm OR carcinoma”, “gene OR allele OR polymorphism OR variation”, and “196a2 OR rs11614913”. Searching was investigated without restriction on publication date and language. We evaluated all potentially associated publications to retrieve the most eligible studies. Reference lists were searched manually to further identify additional eligible literatures.

Inclusion and Exclusion Criteria

The following inclusion criteria were analyzed in selecting studies for the current meta-analysis: (1) evaluation of hsa-miR-196a2 rs11614913 polymorphism and lung cancers; (2) use an independent case-control design studies for human; (3) describing useful allele and genotype frequencies for estimating an odds ratios (ORs) and 95% confidence intervals (95% CIs); (4) only full-text manuscripts were included. The major exclusion criteria were: (1) duplication of the previous publications; (2) abstract, comment, and review; (3) no sufficient data were reported.

Data Extraction

Three investigators (Yuan, Zeng and Yang) extracted all data independently, complied with the inclusion criteria listed above. Discrepancies were adjudicated by other investigators (Wang and Liu) until consensus was achieved on all items. The following items were collected from each eligible publication: the first author’s name, year of publication, country origin, ethnicity, numbers of cases and controls, allele and genotype frequencies for cases and controls, and genotyping method. Different ethnic descents were categorized as Asian and Caucasian.

Statistical Analysis

We performed the PRISMA checklist as protocol of the meta-analysis and followed the guideline (Table S1) [46]. The departure of frequencies of hsa-miR-192a rs11614913 polymorphism from expectation under Hardy-Weinberg equilibrium in the control population was assessed using the goodness-of-fit chi-square test and a P-value < 0.05 was considered significant disequilibrium. The strength of association between hsa-miR-196a2 rs11614913 polymorphisms and susceptibility to lung cancer was evaluated by ORs with 95% CIs. The significance of the pooled ORs was determined by the Z-test, and P-value < 0.05 was considered statistically significant. The pooled ORs were obtained from combination of single studies by homoyzogote comparison (CC versus (vs.) TT), heterozygote comparison (CT vs. TT), dominant and recessive models (CC/CT vs. TT, and CC vs. CT/TT), allele comparison (C vs. T), respectively. Subgroup analyses were investigated by racial descent. The chi-square-based Q-test [47,48] and the I2 index [49] were used to check the heterogeneity among different studies. A P-value < 0.10 and/or I2 index >50% for Q-test indicated the existence of notable heterogeneity among the studies [50], the pooled ORs estimate of each study was calculated by the random-effects model (the DerSimonian and Laird method) [51]. Otherwise, the fixed-effects model (the Mantel-Haenszel method) was employed [52]. Publication bias of literature was diagnosed with Beggs’s funnel plots and Egger’s linear regression method [53]. A P-value less than 0.05 was considered representative of statistically significant publication bias. In the Beggs’s funnel plot, the standard error of logarithm (Log) for OR was plotted against its OR, and Log OR was plotted versus standard error of Log OR for each enrolled study [54]. All analyses were performed with STATA software (version 11.0; STATA Corporation, College Station, TX, USA), and all tests were two-sided.

Results

Characteristics of Eligible Studies

A total of 72 articles were retrieved by literature search from the PubMed, EMBASE, ISI Web of Science, Cochrane Central Register of Controlled Trials, ScienceDirect, Wiley Online Library, CBM and CNKI databases, using different combinations of key terms. As shown in Figure 1, after our selection, 4 case-control studies fulfilled the inclusion criteria [8,10,11,12], including 2219 cases and 2232 controls. There were three studies of Asians and one study of Europeans populations. The genotyping methods were employed in the studies including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), Fluorescence/PCR-melting-curve analysis (PCR-MCA), PCR-high-resolution melting analysis (PCR-HRMA) and Sequencing Taqman. The distribution of genotypes in the controls of all studies did not deviate from Hardy-Weinberg equilibrium (Table 1). Main characteristics of the included publications investigating the association of rs11614913 polymorphism with lung cancers were presented in Table 1.

Meta-analysis Results

There was a distinct variation in the allele frequency of the hsa-miR-196a2 rs11614913C>T polymorphism among the controls across different ethnicities. The C allele frequency of rs11614913C>T polymorphism ranged from 45.27% to 68.60% across Asian and Caucasian controls. In Caucasians controls, the
C allele frequency was 68.60%, which was higher than that in Asian controls (46.05%, \( \chi^2 = 49.59, P < 0.01 \)). Previous studies reported the parallel observations [21,38].

The summary of this meta-analysis for the association strength between rs11614913C>T polymorphism and the susceptibility of lung cancer were shown in Table 2. There was a statistically increased risk of lung cancer in three genetic models (CC vs. TT: OR = 1.26, 95% CI 1.07–1.49, \( P = 0.007 \), Figure 2; CC/CT vs. TT: OR = 1.13, 95% CI 0.98–1.29, \( P = 0.007 \); C vs. T: OR = 1.12, 95% CI 1.03–1.22, \( P = 0.008 \)). Besides, we found a marginal significance in heterozygote comparison (CT vs. TT: OR = 1.15, 95% CI 1.00–1.33, \( P = 0.053 \)). Our data suggested that carriage of the C allele of rs11614913 polymorphism was found to be associated with the increased lung cancer risk. We also performed subgroup analysis for rs11614913C>T polymorphism according to different ethnicities. For the Asian group, significantly increased risk of lung cancer was found in four genetic models (CC vs. TT: OR = 1.30, 95% CI 1.10–1.54, \( P = 0.003 \), Figure 3; CT vs. TT: OR = 1.16, 95% CI 1.01–1.34, \( P = 0.039 \); CC vs. CT/TT: OR = 1.21, 95% CI 1.04–1.41, \( P = 0.012 \); C vs. T: OR = 1.14, 95% CI 1.05–1.25, \( P = 0.002 \)), except for dominant model (CC/CT vs. TT: OR = 1.13, 95% CI 0.99–1.30, \( P = 0.077 \)). As for the Caucasian group, significant association between rs11614913C>T polymorphism and decreased risk of lung cancer was found in recessive model (CC vs. CT/TT: OR = 0.63, 95% CI 0.40–0.98, \( P = 0.04 \)). However, there was no evidence of significant association between the rs11614913C>T polymorphism and the risk of lung cancer in four genetic models (CC vs. TT: OR = 0.50, 95% CI 0.20–1.29, \( P = 0.151 \); CT vs. TT: OR = 0.74, 95% CI 0.30–1.84, \( P = 0.515 \); CC/CT vs. TT: OR = 0.88, 95% CI 0.57–1.34, \( P = 0.767 \); C vs. T: OR = 0.73, 95% CI 0.49–1.07, \( P = 0.107 \)).

**Publication Bias**

Begg’s funnel plot and Egger’s test were performed to evaluate the publication bias of included literatures. The results from this study suggested that no evidence of publication bias was observed in any comparison model (all \( P > 0.05 \)). As shown in Figure 4, the shapes of the funnel plots for homozygote comparison (CC vs. TT)

### Table 1. Characteristics of eligible studies included in the meta-analysis.

| First author | Year | Country | Ethnicity | Genotyping methods | No. (cases/controls) | Case (%) | Control (%) | HWE* |
|--------------|------|---------|-----------|-------------------|---------------------|----------|-------------|------|
| Tian         | 2009 | China   | Asian     | PCR-RFLP          | 1058/1035           | 293 (27.69) | 253 (23.91) | 0.7001|
| Kim          | 2010 | Korea   | Asian     | Fluorescence      | 654/640             | 162 (24.77) | 187 (28.59) | 0.1263|
| Vince        | 2011 | Italy   | Caucasian | PCR-HRMA         | 101/129             | 12 (11.88)  | 35 (34.65) | 0.2670|
| Hong         | 2011 | Korea   | Asian     | TaqMan            | 406/428             | 96 (23.65)  | 224 (55.17) | 0.1631|

*Hardy-Weinberg equilibrium (HWE) was evaluated using the goodness-of-fit chi-square test. \( P \) values were presented. \( P < 0.05 \) was considered representative of a departure from HWE. PCR-RFLP was polymerase chain reaction-restriction fragment length polymorphism. PCR-HRMA was PCR-high-resolution melting analysis.
seemed approximately symmetrical, and Egger’s test did not show significantly statistical evidence of publication bias.

Discussion

Previous studies suggest that miRNAs participate in crucial biological processes and is considered as a key factor in the oncogenesis. Much research effort has been directed toward understanding the role of SNPs present in precursor and mature miRNA and their influences on gene function or expression, cancer susceptibility, and progression of various diseases. The identification of SNPs is important to help predict individual and population risk and understand the pathogenesis of cancer. Many studies demonstrated that the hsa-miR-196a2 rs11614913 SNP was significantly associated with the susceptibility of various cancers such as lung cancer [8,9,10,11,12,13], breast cancer [24,25,26], gastric cancer [27,28], liver cancer [29,30,31], gallbladder cancer [32], prostate cancer [33], esophageal cancer [34,35]. As for lung cancer, Tian et al. found that rs11614913 variant homozygote CC was associated with ~ 25% significantly increased risk of lung cancer compared with the wild-type homozygote TT and heterozygote TC in Chinese population (CC vs. CT/TT: OR = 1.25, 95% CI 1.01–1.54, P = 0.038) [8]. Hong et al. observations suggested that carriers with TT/CC genotype of rs11614913 were predominately increased the survival time of NSCLC Chinese patients. The CC or CT/TT genotypes significantly increased lung cancer risk. Thus, Hu et al. proposed that rs11614913 polymorphism might be a prognostic biomarker for lung cancer [9]. Vinci et al. indicated that a significant increase of hsa-miR-196a2 expression in NSCLC (33.7 ± 8.9) in comparison to paired non-affected tissues (1.9 ± 0.5) was detected (P < 0.001). Furthermore, Vinci et al. found a significant association between rs11614913 CC genotype and high expression, whereas TT genotype showed a very low expression in comparison to both CT (P = 0.005) and CC genotypes (P < 0.01). However, Vinci et al. failed to find any association between rs11614913 genotypes and the risk of NSCLC (P > 0.05) [12]. Yoon et al. proved that, when subdivided by the tumor stage, the rs11614913 genetic variant positively correlated with a better recurrence-free survival (RFS) [adjusted HR = 0.60, 95% CI 0.38–0.94] in patients with stage II and stage III disease. These findings suggested that the rs11614913 polymorphism was associated with prognosis in patients with completely resected NSCLC [13]. Kim found that the CC genotype was associated with a 1.45-fold increased risk of lung cancer compared to the TT genotype in
Figure 3. Forest plots of the association between lung cancer risk and hsa-miR-196a2 rs11614913 polymorphism under homozygote comparison (CC vs. TT) in different ethnicity. OR: odds ratio; CI: confidence interval; I-squared, measure to quantify the degree of heterogeneity in meta-analyses. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight. The diamond represents the pooled OR and 95% CI.

Table 2. Meta-analysis of hsa-miR-196a2 rs11614913 polymorphism and lung cancer risk.

| Comparisons     | Population | N   | OR (95% CI) | Z      | P-value | Model | $\chi^2$ | P-value | I$^2$ (%) |
|-----------------|------------|-----|-------------|--------|---------|-------|---------|---------|----------|
| CC vs. TT       | Overall    | 4   | 1.26 (1.07–1.49) | 2.71   | 0.007   | F     | 4.03    | 0.259   | 25.5     |
|                 | Asian      | 3   | 1.30 (1.10–1.54) | 3.02   | 0.003   | F     | 0.22    | 0.900   | 0        |
|                 | Caucasian  | 1   | 0.50 (0.20–1.29) | 1.44   | 0.151   | F     | –       | –       | –        |
| CT vs. TT       | Overall    | 4   | 1.15 (1.00–1.33) | 1.94   | 0.053   | F     | 5.66    | 0.130   | 47.0     |
|                 | Asian      | 3   | 1.16 (1.01–1.34) | 2.06   | 0.039   | F     | 4.73    | 0.094   | 57.7     |
|                 | Caucasian  | 1   | 0.74 (0.30–1.84) | 0.65   | 0.515   | F     | –       | –       | –        |
| CC/CT vs. TT    | Overall    | 4   | 1.13 (0.98–1.29) | 1.70   | 0.007   | F     | 1.07    | 0.785   | 0        |
|                 | Asian      | 3   | 1.13 (0.99–1.30) | 1.77   | 0.077   | F     | 0.73    | 0.693   | 0        |
|                 | Caucasian  | 1   | 0.88 (0.37–2.06) | 0.30   | 0.767   | F     | –       | –       | –        |
| CC vs. CT/TT    | Overall    | 4   | 1.04 (0.80–1.36) | 0.31   | 0.756   | R     | 8.67    | 0.034   | 65.4     |
|                 | Asian      | 3   | 1.21 (1.04–1.41) | 2.50   | 0.012   | F     | 1.15    | 0.563   | 0        |
|                 | Caucasian  | 1   | 0.63 (0.40–0.98) | 2.05   | 0.040   | F     | –       | –       | –        |
| C vs. T         | Overall    | 4   | 1.12 (1.03–1.22) | 2.66   | 0.008   | F     | 5.34    | 0.149   | 43.8     |
|                 | Asian      | 3   | 1.14 (1.05–1.25) | 3.08   | 0.002   | F     | 0.32    | 0.854   | 0        |
|                 | Caucasian  | 1   | 0.73 (0.49–1.07) | 1.61   | 0.107   | F     | –       | –       | –        |

N, number of comparisons; OR, odds ratio; CI, confidence interval; vs., versus; CC vs. TT: Homozygote comparison; CT vs. TT: Heterozygote comparison; CC/CT vs. TT: Dominant model; CC vs. CT/TT: Recessive model; C vs. T: Allele comparison; R, random effect model; F, fixed effect model; Random effect model was chosen when $P$-value $<0.10$ and/or $I^2 >50\%$ for heterogeneity test; otherwise fixed effect model was used.

doi:10.1371/journal.pone.0061047.g003

doi:10.1371/journal.pone.0061047.t002
Included in this updated meta-analysis [8,10,11,12], including eligible case-control studies (2219 cases and 2232 controls) were without limiting publication date and language. A total of 4 rs11614913 polymorphism and lung cancer risk through conducting focus on lung cancer, we systematically summarized all available case-control studies concerning the relationship between the hsa-miR-196a2 rs11614913 polymorphism and lung cancer risk. Furthermore, only one significant association with decreased lung cancer risk was found in recessive model (P = 0.040, Table 2). Thus, the C allele of rs11614913 polymorphism may contribute to increased lung cancer risk in Asians, but decreased in Europeans, suggesting potentially different mechanisms in different ethnicity based on the different genetic background and the environment they lived in [45,55].

Several previous meta-analyses have been carried out to reveal the potential associations of the hsa-miR-196a2 rs11614913 polymorphism with overall cancer susceptibility. Xu et al. [15], He et al. [43] and Wang et al. [44] both identified that the T allele or its carriers of rs11614913 polymorphism were associated with overall decreased cancer risk. In another meta-analysis, overall increased cancer risk with the C allele or its carriers of rs11614913 polymorphism were found in all genetic models (P<0.05) [45]. In stratified analysis by cancer types, He et al. [43], Wang et al. [44] and Wang et al. [45] found that the rs11614913 polymorphism was significantly associated with lung cancer risk in subgroup analysis. But the subgroup analysis only included three studies and Asian ethnicity [8,10,11]. To date, there is no meta-analysis with focus on the association between of hsa-miR-196a2 rs11614913 polymorphism and lung cancer risk. There were some of the previous meta-analyses evaluated the association of rs11614913 polymorphism and lung cancer by means of subgroup analysis [15,43,44,45]. Unfortunately, the reliability of the conclusions was limited across these meta-analyses which may at least partly due to the fact that none of these meta-analyses enrolled all available case-control studies concerning the relationship between rs11614913 polymorphism and lung cancer risk. Furthermore, when regarding with the ethnicity, only Asians populations were included in these meta-analyses. In the current meta-analysis, with focus on lung cancer, we systematically summarized all available up-to-date case-control studies on the association between rs11614913 polymorphism and lung cancer risk through conducting to comprehensive literature search in multiple databases without limiting publication date and language. A total of 4 eligible case-control studies (2219 cases and 2232 controls) were included in this updated meta-analysis [8,10,11,12], including three studies of Asians and one study of Europeans populations (Table 1). Our study suggested that the presence of C allele significantly increased the risk of lung cancer with the comparison to T allele. Moreover, the rs11614913 polymorphism was found to be associated with a significantly increased lung cancer risk in the CC homozygote and CC/CT genotype as opposed to the TT homozygote (Table 2). In the subgroup of ethnicity, we detected significant association between the rs11614913 polymorphism and increased risk of lung cancers in Asians (Table 2). Interestingly, on the contrary, we found that the rs11614913 polymorphism could be potential associated with decreased lung cancer risk in Caucasians, while only one significant association with decreased lung cancer risk was found in recessive model (P = 0.040, Table 2).

Effects of rs11614913 on Lung Cancer Risk
Some advantages can be highlighted in the current study. Firstly, our study shed light on the association between hsa-miR-196a2 polymorphism and increased risk of lung cancer systematically and comprehensively. Secondly, according to our selection criteria, all included studies in our meta-analysis had acceptable quality, and the sources of cases and controls were collected from all included studies, which significantly increased the statistical power. Thirdly, no evidence of publication bias was observed, indicating that the whole pooled results may be unbiased. Fourthly, our study suggested that functional polymorphism of hsa-miR-196a2 could be conducted and replicate these observations, therefore it could be beneficial to detect novel mechanism to forecast the risk of lung cancer. However, some limitations of this study should be noticed in our meta-analysis at the same time. First, lack of the original data of the included studies limited our further evaluation of the potential interactions, because genetic factors, tumor biological characteristics and their interactions with environmental factors may modulate lung cancer risk. A more precise analysis with an adjustment estimate could be conducted if individual data were available. Second, in this meta-analysis, only published studies were included, ongoing studies and unpublished data were not sought, which may have biased our results. Third, the included case-control studies were carried out from Asians (Chinese and Korean populations) and Caucasians (Italian populations). Therefore, results from this meta-analysis may be applicable only to these ethnic populations.

In conclusion, despite the limitation, our meta-analysis suggested that the hsa-miR-196a2 polymorphism may contribute to genetic susceptibility for increased lung cancer risk, especially in Asian populations. The rs11614913 polymorphism could be considerably acted as a candidate biomarker for lung cancer screening, diagnosis and therapy in the future. To confirm our findings, further well-designed studies with large sample size in diverse ethnic populations should be performed to validate the association.

Supporting Information

Table S1 PRISMA 2009 Checklist.

Author Contributions

Designed the study: ZL. Conceived and designed the experiments: ZY ZL. Performed the experiments: ZY XZ DY WW ZL. Analyzed the data: ZY WW ZL. Contributed reagents/materials/analysis tools: ZY WW ZL. Wrote the paper: ZY ZL.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153–156.
2. Biaoxue R, Shuanying Y, Wei L, Wei Z, Zongjuan M (2012) Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol 10: 170.
3. Sekido Y, Fong KM, Minna JD (2003) Molecular genetics of lung cancer. Annu Rev Med 54: 73–87.
4. Meyerson M, Carbone D (2005) Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 23: 3219–3226.
5. Gravalle CA, Dennis PA (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32: 169–176.
6. Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1: 49–52.
7. Yanahara N, Caplen N, Bowman E, Seike M, Kumanoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.
8. Tien T, Shu Y, Chen J, Hu Z, Xu L, et al. (2009) A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 18: 1183–1187.
9. Ho Z, Chen J, Tian T, Zhou X, Gu H, et al. (2008) Genetic variants of microRNA sequences and non-small cell lung cancer survival. J Clin Invest 118: 2600–2608.
10. Kim MJ, Yoo SS, Choi YY, Park JY (2010) A functional polymorphism in the pre-microRNA-196a-2 gene polymorphism with gastric cancer risk in a Korean population. Lung Cancer 68: 127–129.
11. Hong YS, Kang HJ, Kwak JY, Park BI, You CH, et al. (2011) Association between microRNA196a2 rs11614913 genotypes and the risk of non-small cell lung cancer in Korean population. J Prev Med Public Health 44: 125–130.
12. Vinci S, Gelmini S, Prato N, Conti S, Malencca F, et al. (2011) Genetic variants in miR-196a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med 49: 2073–2080.
13. Yoon KA, Yoon H, Park S, Jang HJ, Zo JJ, et al. (2012) The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer. J Thorac Cardiovasc Surg 144(4): 794–807.
14. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
15. Xu W, Xu J, Liu S, Chen B, Wang X, et al. (2011) Effects of common polymorphisms rs11614913 in miR-196a2 and rs2910164 in miR-146a on cancer susceptibility: a meta-analysis. PLoS One 6: e20471.
16. Xu P, Guo M, Hay BA (2004) MicroRNAs and the regulation of cell death. Trends in genetics - TIG 20: 617–624.
17. Bartel DP, Chen CZ (2004) Micromanager of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5: 396–400.
18. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, et al. (2008) Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29: 579–584.
19. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857–866.
20. Chen K, Song F, Calin GA, Wei Q, Hao X, et al. (2008) Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 29: 1306–1311.
21. Chu H, Wang M, Shi D, Ma L, Zhang Z, et al. (2011) Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PLoS One 6: e18108.
22. Wang Z, Gao Y, Jiang C, Yang G, Wu J, et al. (2012) Lack of Association of Two Common Polymorphisms rs2910164 and rs11614913 with Susceptibility to Hepatocellular Carcinoma: A Meta-Analysis. PLoS One 7: e40039.
23. Saunders MA, Liang H, Li WH (2007) Human polymorphism at microRNA and microRNA target sites. Proc Natl Acad Sci U S A 104: 3300–3305.
24. Hu Z, Liang J, Wang Z, Tian T, Zhou X, et al. (2009) Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat 30: 79–84.
25. Hoffmann AE, Zheng T, Yi C, Leaderer D, Weidhaas J, et al. (2010) microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 69: 5970–5977.
26. Cuticchi I, Yang R, Verderio P, Pizzamiglio S, Hessen L, et al. (2010) Evaluation of miR-196a and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat 31: E1052–E1057.
27. Peng S, Kuang Z, Sheng C, Zhang Y, Xu H, et al. (2010) Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci 55: 2299–2303.
28. Okubo M, Tahara T, Shibata T, Yahashita H, Nakamura M, et al. (2010) Association between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese population. Helicobacter 15: 524–531.
29. Li XD, Li ZG, Song XX, Liu CF (2010) A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology 42: 669–673.
30. Qi P, Dou TH, Geng L, Zhou FG, Gu X, et al. (2010) Association of a variant in miR-196a2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum Immunol 71: 621–626.
31. Akdz H, Bayram S, Bekar A, Akgollu E, Ulger Y (2011) A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepat 18: e399–407.
32. Srivastava K, Srivastava A, Mittal B (2010) Common genetic variants in pre-microRNAs and risk of gallbladder cancer in North Indian population. J Hum Genet 55: 495–499.
33. George GP, Gangour R, Mandal RK, Sankhwar SN, Mittal RD (2011) Genetic variation in microRNA genes and prostate cancer risk in North Indian population. Mol Biol Rep 38: 1609–1615.
34. Ye Y, Wang KK, Gu J, Yang H, Lin J, et al. (2008) Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) 1: 460–469.
35. Wang K, Guo H, Hu H, Xiong G, Guan X, et al. (2010) A functional variation in pre-microRNA-196a is associated with susceptibility of esophageal squamous cell carcinoma risk in Chinese Han. Biomarkers 15: 614–618.
36. Dou T, Wu Q, Chen X, Ribas J, Xi X, et al. (2010) A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population. Cancer Res Clin Oncol 136: 1833–1839.
37. Liu Z, Li G, Wei S, Niu J, El-Naggar AK, et al. (2010) Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer 116: 4753–4760.
38. Guo J, Jin M, Zhang M, Chen K (2012) A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS One 7: e36235.
39. Qiu LX, Wang Y, Xia ZG, Xi B, Mao C, et al. (2011) miR-196a2 C allele is a low-penetrant risk factor for cancer development. Cytokine 56: 589–592.
40. Tian T, Xu Y, Bai J, Wu J, Shen H, et al. (2010) Functional polymorphisms in two pre-microRNAs and cancer risk: a meta-analysis. Int J Mol Epidemiol Genet 1: 358–366.
41. Wang F, Ma YL, Zhang P, Yang JJ, Chen HQ, et al. (2012) A genetic variant in microRNA-196a2 is associated with increased cancer risk: a meta-analysis. Mol Biol Rep 39: 269–275.
42. Gao LB, Bai P, Pan XM, Jia J, Li LJ, et al. (2011) The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 125: 571–574.
43. He B, Pan Y, Cho WC, Xu Y, Gu L, et al. (2012) The association between four genetic variants in microRNAs (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: evidence from published studies. PLoS One 7: e49032.
44. Wang J, Wang Q, Liu H, Shao N, Tan B, et al. (2012) The association of miR-196a2 rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis 27: 779–788.
45. Wang P, Xie S, Cui A, Zhang Y, Jiang B (2012) miR-196a2 polymorphisms and susceptibility to cancer: A meta-analysis involving 24,697 subjects. Esp Ther Med 3: 324–330.
46. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097.
47. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10: 101–129.
48. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
49. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 537–540.
50. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Am J Intern Med 127: 820–826.
51. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
52. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
53. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
54. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.